|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsors and Collaborators: |
Centre Henri Becquerel Ligue contre le Cancer |
| Information provided by: | Centre Henri Becquerel |
| ClinicalTrials.gov Identifier: | NCT00195897 |
Purpose
Anthracycline-based chemotherapy is a key point of the treatment of patients with Hodgkin's and non-Hodgkin's lymphomas. However, cumulative doses are limited by cardiotoxicity, resulting in a marked left ventricular function impairment that may lead to heart failure.
The standard clinical approach to monitoring for anthracycline cardiotoxicity is based on cardiac function monitoring using echocardiography or radionuclide angiography. The aim of this study is to evaluate the usefulness of biochemical markers of cardiac injury (troponin and NT-proBNP) and structural changes on cardiac MR in predicting anthracycline cardiotoxicity.
| Condition |
|
Lymphoma Heart Failure, Congestive |
| MedlinePlus related topics: | Heart Failure Lymphoma |
| Study Type: | Observational |
| Study Design: | Screening, Longitudinal, Defined Population, Prospective Study |
| Official Title: | Early Assessment of Anthracycline-Induced Cardiotoxicity: Usefulness of Biochemical Markers and Ventricular Function Assessment. |
Eligibility
| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Alain Manrique, MD | +33 232 082 258 | alain.manrique@univ-rouen.fr |
| Contact: Marc Thillays | +33 232 082 497 | marc.thillays@rouen.fnclcc.fr |
| France | |||||
| Centre Henri Becquerel | Not yet recruiting | ||||
| Rouen, France, 76038 | |||||
| Contact: Marc Thillays +33 232 082 497 marc.thillays@rouen.fnclcc.fr | |||||
| Contact: Martine Ballot +33 232 082 544 martine.ballot@rouen.fnclcc.fr | |||||
| Sub-Investigator: Hervé Tilly, MD | |||||
| Sub-Investigator: Stephane Lepretre, MD | |||||
| Sub-Investigator: Pascal Lenain, MD | |||||
| Sub-Investigator: Nathalie Contentin, MD | |||||
| Sub-Investigator: Aspasia Stamatoulas, MD | |||||
| Sub-Investigator: Pierre Vera, MD | |||||
| Sub-Investigator: Anne Hitzel, MD | |||||
| Principal Investigator: Fabrice Jardin, MD | |||||
| University Hospital of Rouen | Not yet recruiting | ||||
| Rouen, France, 76031 | |||||
| Contact: Jean Nicolas Dacher, MD +33 232 888 990 Jean-Nicolas.Dacher@chu-rouen.fr | |||||
| Principal Investigator: Jean Nicolas Dacher, MD | |||||
| Sub-Investigator: Bruno Cauliez, MD | |||||
| Sub-Investigator: Alain Lavoinne, MD | |||||
| Centre Henri Becquerel |
| Ligue contre le Cancer |
| Study Chair: | Alain Manrique, MD | Centre Henri Becquerel |
| Principal Investigator: | Fabrice Jardin, MD | Centre Henri Becquerel |
More Information
| Study ID Numbers: | 2005-001-CHB |
| First Received: | September 12, 2005 |
| Last Updated: | September 12, 2005 |
| ClinicalTrials.gov Identifier: | NCT00195897 |
| Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
|
|
|
|